Tag: VERS
Potentially Inappropriate Medications Linked to Frailty at Cancer Diagnosis
Each additional Geriatric Oncology-PIM linked to 66 percent increase in odds of being mildly, moderate-to-severely frail at diagnosis
β-Blockers Not Beneficial After MI Without Reduced Left Ventricular Ejection Fraction
Second study shows beneficial effects for patients with myocardial infarction and mildly reduced LVEF
Women Have Worse Outcomes Than Men With Beta-Blockers After Acute MI
Incidence of primary end point of death, MI, heart failure hospitalization up with beta-blockers in women, but not in men
FDA Now Providing Daily Updates on Adverse Events
To increase transparency, the agency is publishing data from the FDA Adverse Event Reporting System daily rather than quarterly
Semaglutide Not Linked to Increased Risk of Eye Disorders, Diabetic Retinopathy
Semaglutide linked to increased risk of nonarteritic anterior ischemic optic neuropathy, but evidence remains insufficient to establish definitive conclusion
COVID-19 mRNA Vaccine Targeting Omicron JN.1 Lineage Safe
No significant increases seen in rate of hospital contacts for any of 29 adverse events in 28-day risk period after vaccination
GLP-1 Receptor Agonist Use Linked to Nonarteritic Anterior Ischemic Optic Neuropathy
Association seen in seniors with type 2 diabetes; greater associations seen for semaglutide and liraglutide
Glipizide Linked to Highest MACE-4 Risk in Individuals With Type 2 Diabetes
Highest risk seen with glipizide versus other sulfonylureas and DPP4 inhibitors as second-line therapy
Standardization Needed for Dialysis Initiation in Pregnancy
Women who started dialysis during pregnancy more often had adverse maternal and fetal outcomes
GLP-1 Receptor Agonist Use in T2D Tied to Increased Risk for GERD, GERD Complications
Risk ratios were 1.27 and 1.55 for GERD and its complications during a median follow-up of three years for GLP-1 RA versus SGLT-2 inhibitor users